[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-001", "question": "A 3-day-old term neonate presents with progressive cyanosis unresponsive to supplemental oxygen. Echocardiography reveals d-transposition of the great arteries with intact ventricular septum and a restrictive patent foramen ovale. Prostaglandin E1 infusion is initiated but cyanosis persists with oxygen saturation of 55%. The infant is hemodynamically stable with adequate biventricular function. Which of the following is the most appropriate next step in management?", "options": ["Emergent arterial switch operation", "Balloon atrial septostomy", "Extracorporeal membrane oxygenation", "Inhaled nitric oxide therapy", "Atrial septectomy via median sternotomy"], "answer": "B", "answer_index": 1, "explanation": "In d-TGA with intact ventricular septum and restrictive atrial communication, balloon atrial septostomy (Rashkind procedure) is the urgent intervention to improve mixing at the atrial level. PGE1 maintains ductal patency but cannot improve atrial mixing when the foramen ovale is restrictive. Arterial switch is definitive but requires stabilization first. ECMO is reserved for refractory cases after septostomy. Surgical septectomy is more invasive and reserved for failed balloon septostomy.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to analyze the clinical scenario of a neonate with d-transposition of the great arteries (d-TGA).\n\nThe key findings are:\n- 3-day-old term neonate with progressive cyanosis\n- Unresponsive to supplemental oxygen\n- d-TGA with intact ventricular septum\n- Restrictive patent foramen ovale (PFO)\n- Prostaglandin E1 initiated but cyanosis persists (O2 sat 55%)\n- Hemodynamically stable with good biventricular function\n\nIn d-TGA, the aorta arises from the right ventricle and the pulmonary artery from the left ventricle, creating two parallel circulations. Mixing between these circulations is essential for survival. The restrictive PFO is limiting this mixing, which explains why the infant remains cyanotic despite PGE1 (which typically keeps the ductus arteriosus open to allow mixing).\n\nThe most urgent need is to improve mixing between the circulations. Balloon atrial septostomy (Rashkind procedure) is the procedure of choice in this scenario as it creates an adequate atrial communication to improve mixing, which will stabilize the infant until definitive surgical correction can be performed.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-002", "question": "A 58-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab presents with 6 weeks of progressive dyspnea and dry cough. HRCT shows diffuse ground-glass opacities with areas of consolidation in a peribronchovascular distribution. Bronchoalveolar lavage reveals 45% lymphocytes with CD4/CD8 ratio of 0.5. Methotrexate pneumonitis is suspected. Which histopathologic pattern is most commonly associated with methotrexate-induced lung toxicity?", "options": ["Usual interstitial pneumonia", "Diffuse alveolar damage", "Hypersensitivity pneumonitis pattern", "Organizing pneumonia", "Pulmonary alveolar proteinosis"], "answer": "C", "answer_index": 2, "explanation": "Methotrexate-induced lung toxicity most commonly manifests as a hypersensitivity pneumonitis pattern, characterized by lymphocytic alveolitis with low CD4/CD8 ratio, granulomas, and interstitial inflammation. The BAL findings of elevated lymphocytes with inverted CD4/CD8 ratio support this diagnosis. While organizing pneumonia and diffuse alveolar damage can occur, hypersensitivity pneumonitis is the predominant pattern. UIP pattern is more characteristic of RA-ILD itself rather than drug toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to consider the histopathologic patterns associated with methotrexate-induced lung toxicity.\n\nMethotrexate pneumonitis typically presents with:\n- Acute or subacute onset of dyspnea and dry cough\n- Radiographic findings of ground-glass opacities and consolidation\n- Lymphocytic predominance on bronchoalveolar lavage with reduced CD4/CD8 ratio\n\nThe most common histopathologic pattern in methotrexate-induced lung toxicity is a hypersensitivity pneumonitis-like reaction. This pattern shows:\n- Interstitial inflammation with lymphocytic infiltration\n- Poorly formed granulomas\n- Cellular bronchiolitis\n- The reduced CD4/CD8 ratio (0.5) in this case is characteristic of hypersensitivity pneumonitis\n\nWhile organizing pneumonia can also be seen with methotrexate toxicity, it is less common than the hypersensitivity pneumonitis pattern. Diffuse alveolar damage may occur in acute presentations, but is not the most common pattern. Usual interstitial pneumonia and pulmonary alveolar proteinosis are not typically associated with methotrexate lung toxicity.\n\nThe answer is (C)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-003", "question": "A 32-year-old woman at 28 weeks gestation presents with severe preeclampsia. Despite magnesium sulfate and labetalol, she develops pulmonary edema requiring intubation. Echocardiography shows preserved ejection fraction of 65% with grade III diastolic dysfunction and elevated E/e' ratio of 18. Central venous pressure is 4 mmHg. Which pathophysiologic mechanism best explains her pulmonary edema?", "options": ["Systolic heart failure from peripartum cardiomyopathy", "Increased pulmonary capillary permeability from endothelial dysfunction", "Volume overload from iatrogenic fluid administration", "Diastolic dysfunction from acute afterload mismatch", "Mitral regurgitation from papillary muscle dysfunction"], "answer": "D", "answer_index": 3, "explanation": "Severe preeclampsia causes acute hypertensive crisis leading to afterload mismatch. The preserved EF with grade III diastolic dysfunction and elevated E/e' indicates heart failure with preserved ejection fraction due to impaired ventricular relaxation from acute pressure overload. The low CVP argues against volume overload. While endothelial dysfunction occurs in preeclampsia, the echocardiographic findings point to diastolic dysfunction as the primary mechanism. Peripartum cardiomyopathy would show reduced systolic function.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To determine the best explanation for this patient's pulmonary edema, I'll analyze the key findings:\n\n1) Severe preeclampsia at 28 weeks gestation\n2) Preserved ejection fraction (65%)\n3) Grade III diastolic dysfunction\n4) Elevated E/e' ratio of 18 (indicates elevated left atrial pressure)\n5) Low central venous pressure (4 mmHg)\n\nOption A (Systolic heart failure) is incorrect because her ejection fraction is preserved at 65%.\n\nOption B (Increased pulmonary capillary permeability) is plausible since preeclampsia causes endothelial dysfunction, which can lead to increased vascular permeability.\n\nOption C (Volume overload) is unlikely given the low central venous pressure of 4 mmHg.\n\nOption E (Mitral regurgitation) has no supporting evidence in the case.\n\nOption D (Diastolic dysfunction from acute afterload mismatch) best explains the findings. Preeclampsia causes severe hypertension (increased afterload), which can lead to acute diastolic dysfunction despite preserved systolic function. The elevated E/e' ratio confirms high left ventricular filling pressures, while the normal ejection fraction and grade III diastolic dysfunction support this mechanism.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-004", "question": "A 67-year-old man with ischemic cardiomyopathy (EF 25%) and cardiac resynchronization therapy-defibrillator presents after appropriate ICD shock for ventricular tachycardia. He is on maximally tolerated guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Electrophysiology study reveals scar-related reentrant VT from the inferolateral left ventricle. Catheter ablation is performed. Three months later, he has recurrent VT storm despite amiodarone. Which additional pharmacologic therapy has demonstrated mortality benefit in this specific population?", "options": ["Mexiletine", "Sotalol", "Ranolazine", "Quinidine", "Dofetilide"], "answer": "A", "answer_index": 0, "explanation": "Mexiletine, a class IB sodium channel blocker, when added to amiodarone in patients with recurrent VT despite amiodarone monotherapy, has shown reduction in VT recurrence and ICD shocks. The MEXICA trial demonstrated this combination's efficacy. Sotalol and dofetilide have proarrhythmic risks in low EF patients. Quinidine has significant toxicity and limited modern data. Ranolazine has some antiarrhythmic properties but lacks robust evidence in scar-related VT. Mexiletine's synergistic sodium channel blockade with amiodarone provides additional substrate modification.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To answer this question, I need to consider which antiarrhythmic medication has demonstrated mortality benefit specifically in patients with ischemic cardiomyopathy, reduced ejection fraction, and recurrent ventricular tachycardia despite amiodarone therapy.\n\nLet me analyze each option:\n\nA. Mexiletine: This is a Class IB antiarrhythmic that can be used as adjunctive therapy with amiodarone for VT suppression, but it has not demonstrated mortality benefit in this specific population.\n\nB. Sotalol: This is a Class III antiarrhythmic with beta-blocking properties. While it can be used for VT, it has not shown mortality benefit in this specific scenario and may worsen heart failure due to negative inotropic effects.\n\nC. Ranolazine: This antianginal medication has some antiarrhythmic properties but lacks proven mortality benefit in this specific population.\n\nD. Quinidine: This is a Class IA antiarrhythmic that can be used for refractory VT, particularly in Brugada syndrome, but has not demonstrated mortality benefit in ischemic cardiomyopathy patients with VT storm.\n\nE. Dofetilide: This is a Class III antiarrhythmic that can be used for atrial fibrillation but has not demonstrated mortality benefit specifically for ventricular arrhythmias in this population.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-005", "question": "A 6-year-old boy presents with recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2. Episodes resolve spontaneously within 5 days. Between episodes, he is completely well with normal growth. Laboratory studies during an episode show elevated CRP and ESR with normal complete blood count. Genetic testing for FMF, TRAPS, and HIDS mutations is negative. Which treatment has the highest likelihood of inducing complete remission?", "options": ["Colchicine prophylaxis", "Anakinra during episodes", "Single-dose corticosteroid at episode onset", "Tonsillectomy with or without adenoidectomy", "Cimetidine prophylaxis"], "answer": "D", "answer_index": 3, "explanation": "PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) is the most common periodic fever syndrome in children. While corticosteroids abort individual episodes, they may shorten the interval between attacks. Tonsillectomy (with or without adenoidectomy) achieves complete resolution in 63-95% of patients and is considered curative. Colchicine and cimetidine have variable efficacy for prophylaxis. Anakinra is reserved for refractory cases. The classic presentation with negative genetic testing and stereotypical episodes strongly supports PFAPA, where tonsillectomy offers the best chance of definitive cure.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To answer this question, I need to identify the condition and determine the most effective treatment.\n\nThe patient presents with:\n- Recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis\n- Regular pattern (every 4-6 weeks)\n- Self-limited episodes (5 days)\n- Completely well between episodes\n- Normal growth\n- Elevated inflammatory markers during episodes\n- Negative genetic testing for other periodic fever syndromes\n\nThis clinical picture is consistent with PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis), a periodic fever syndrome of childhood.\n\nFor PFAPA syndrome treatment options:\n- Colchicine has modest efficacy for prophylaxis\n- Anakinra can help during episodes but doesn't induce complete remission\n- Single-dose corticosteroids are effective for aborting individual episodes\n- Tonsillectomy with or without adenoidectomy has been shown to induce complete remission in a high percentage of PFAPA patients\n- Cimetidine prophylaxis has limited evidence for efficacy\n\nBased on the literature, tonsillectomy has the highest likelihood of inducing complete remission in PFAPA syndrome.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-006", "question": "A 45-year-old woman with systemic lupus erythematosus develops acute kidney injury with serum creatinine rising from 1.0 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous RBC casts, and dysmorphic red cells. Complement levels are low. Kidney biopsy reveals diffuse proliferative glomerulonephritis (Class IV-G) with 40% cellular crescents, wire loop lesions, and activity index of 14/24 with chronicity index of 2/12. Anti-dsDNA antibody titer is markedly elevated. Which induction regimen has demonstrated superior renal response rates in this clinical scenario?", "options": ["Mycophenolate mofetil plus glucocorticoids", "Cyclophosphamide (Euro-Lupus protocol) plus glucocorticoids", "Voclosporin plus mycophenolate mofetil plus glucocorticoids", "Rituximab plus mycophenolate mofetil plus glucocorticoids", "Belimumab plus cyclophosphamide plus glucocorticoids"], "answer": "C", "answer_index": 2, "explanation": "The AURORA trial demonstrated that voclosporin added to mycophenolate mofetil and low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23%) at 52 weeks compared to MMF and glucocorticoids alone in active lupus nephritis. This triple therapy showed benefit across Class III, IV, and V lupus nephritis. While MMF and cyclophosphamide are established induction agents, the addition of voclosporin (a novel calcineurin inhibitor) provides superior efficacy. Rituximab and belimumab combinations lack the same level of evidence for superior renal response in this setting.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To answer this question, I need to consider the best induction therapy for severe lupus nephritis.\n\nThe patient has:\n- Class IV-G lupus nephritis (diffuse proliferative glomerulonephritis)\n- High disease activity (40% crescents, high activity index of 14/24)\n- Low chronicity index (2/12)\n- Markedly elevated anti-dsDNA antibodies\n- Low complement levels\n- Significant acute kidney injury\n\nFor severe lupus nephritis (Class IV) with high disease activity, the standard induction therapies with the strongest evidence base are:\n\n1. Cyclophosphamide plus glucocorticoids\n2. Mycophenolate mofetil (MMF) plus glucocorticoids\n\nMajor trials (including the ALMS trial) have shown that MMF is generally as effective as cyclophosphamide for induction therapy in lupus nephritis, with potentially fewer adverse effects.\n\nFor severe, rapidly progressive disease with crescents, cyclophosphamide has traditionally been preferred, though recent evidence suggests MMF may be equally effective in many cases.\n\nVoclosporin, rituximab, and belimumab have been studied as add-on therapies, but they are not considered first-line induction therapies for severe lupus nephritis with this presentation.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-007", "question": "A 72-year-old man is admitted to the ICU with septic shock from pneumonia. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, MAP remains 58 mmHg. Echocardiography shows hyperdynamic left ventricle with EF 75%, small LV cavity, and IVC diameter of 0.8 cm with >50% respiratory variation. Lactate is 6.2 mmol/L. Which vasopressor strategy is most appropriate?", "options": ["Add vasopressin 0.03 units/min", "Add epinephrine infusion", "Add phenylephrine infusion", "Add angiotensin II infusion", "Increase norepinephrine to maximum dose before adding second agent"], "answer": "A", "answer_index": 0, "explanation": "Current sepsis guidelines recommend adding vasopressin (up to 0.03 units/min) as the second-line vasopressor when norepinephrine fails to achieve target MAP, typically when norepinephrine exceeds 0.25-0.5 mcg/kg/min. Vasopressin acts via V1 receptors independent of catecholamine pathways, which may be downregulated in sepsis. The VASST trial showed potential mortality benefit in less severe septic shock. The echocardiographic findings suggest adequate volume status (small IVC with variation indicates fluid responsiveness is exhausted). Angiotensin II is reserved for refractory vasodilatory shock after multiple agents. Phenylephrine may reduce cardiac output.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To answer this question, I need to analyze the patient's condition and the most appropriate vasopressor strategy.\n\nThe patient is a 72-year-old man with septic shock from pneumonia who remains hypotensive (MAP 58 mmHg) despite fluid resuscitation and a moderate dose of norepinephrine (0.5 mcg/kg/min). \n\nKey findings:\n- Hyperdynamic left ventricle (EF 75%)\n- Small LV cavity\n- IVC diameter of 0.8 cm with >50% respiratory variation (suggesting hypovolemia)\n- Elevated lactate (6.2 mmol/L) indicating tissue hypoperfusion\n\nThe echocardiographic findings suggest the patient may still be volume responsive (small IVC with respiratory variation). However, the question states \"despite adequate fluid resuscitation,\" so we should focus on vasopressor management.\n\nFor septic shock with persistent hypotension despite norepinephrine:\n- Vasopressin (0.03 units/min) is recommended as a second-line agent in septic shock to reduce norepinephrine requirements and improve MAP\n- Epinephrine can increase cardiac output but may worsen tachycardia and lactic acidosis\n- Phenylephrine is primarily an alpha-agonist without beneficial beta effects\n- Angiotensin II is a newer agent but not first-line for septic shock\n- Increasing norepinephrine to maximum doses before adding a second agent is not recommended as it increases risk of adverse effects\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-008", "question": "A 29-year-old primigravida at 34 weeks gestation presents with sudden-onset severe headache and right-sided weakness. Blood pressure is 178/112 mmHg. CT head shows left parietal intracerebral hemorrhage with surrounding edema. MRV demonstrates absence of flow in the superior sagittal sinus and left transverse sinus consistent with cerebral venous thrombosis. Platelet count is 82,000/μL, LDH is elevated, and peripheral smear shows schistocytes. Which is the most appropriate immediate management?", "options": ["Emergent cesarean delivery followed by therapeutic anticoagulation", "Therapeutic anticoagulation with unfractionated heparin", "Platelet transfusion followed by decompressive craniectomy", "Plasma exchange followed by anticoagulation", "Magnesium sulfate and antihypertensives with delayed anticoagulation"], "answer": "A", "answer_index": 0, "explanation": "This patient has cerebral venous thrombosis complicated by hemorrhagic transformation in the setting of HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) evidenced by thrombocytopenia, elevated LDH, and schistocytes. The definitive treatment for HELLP is delivery. While anticoagulation is standard for CVT even with hemorrhage, the underlying HELLP syndrome will not resolve without delivery and may worsen, increasing bleeding risk. Emergent cesarean delivery addresses the root cause, after which therapeutic anticoagulation can be safely initiated. Plasma exchange is for TTP, not HELLP. Delaying anticoagulation without addressing HELLP is inappropriate.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient presents with several concerning findings:\n- Severe hypertension (178/112 mmHg)\n- Neurological symptoms (headache, right-sided weakness)\n- Intracerebral hemorrhage\n- Cerebral venous thrombosis\n- Laboratory findings consistent with microangiopathy (thrombocytopenia, elevated LDH, schistocytes)\n\nThese findings suggest thrombotic thrombocytopenic purpura (TTP) or HELLP syndrome in the setting of preeclampsia with severe features. The presence of schistocytes, thrombocytopenia, and elevated LDH points toward a microangiopathic hemolytic anemia.\n\nGiven the cerebral venous thrombosis with hemorrhagic conversion, immediate anticoagulation alone (option B) would be risky without addressing the underlying microangiopathy.\n\nPlatelet transfusion (option C) would be contraindicated in TTP as it could worsen thrombosis.\n\nMagnesium and antihypertensives (option E) address preeclampsia but don't treat the microangiopathy or thrombosis.\n\nEmergent delivery (option A) would help with preeclampsia but doesn't address the microangiopathy.\n\nPlasma exchange (option D) is the first-line treatment for TTP and would address the microangiopathy, followed by anticoagulation for the cerebral venous thrombosis once the risk of hemorrhage is reduced.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-009", "question": "A 14-year-old girl presents with 3 months of progressive fatigue, arthralgia, and facial rash. Laboratory evaluation reveals ANA 1:1280 (homogeneous pattern), anti-dsDNA positive, anti-Smith positive, C3 45 mg/dL (normal 90-180), C4 6 mg/dL (normal 10-40), and anti-C1q antibodies positive. Urinalysis shows 2+ protein and 10-15 RBCs/hpf. She is diagnosed with juvenile-onset systemic lupus erythematosus. The presence of anti-C1q antibodies in this patient most specifically predicts which disease manifestation?", "options": ["Neuropsychiatric lupus", "Proliferative lupus nephritis", "Antiphospholipid syndrome", "Lupus pneumonitis", "Autoimmune hemolytic anemia"], "answer": "B", "answer_index": 1, "explanation": "Anti-C1q antibodies have the highest specificity for lupus nephritis, particularly proliferative forms (Class III/IV). Studies demonstrate that anti-C1q antibodies have a negative predictive value approaching 100% for active renal disease-their absence essentially excludes active nephritis. The combination of anti-C1q with anti-dsDNA antibodies and low complement strongly predicts proliferative nephritis. While anti-C1q can be seen in hypocomplementemic urticarial vasculitis, in SLE context, they specifically correlate with renal involvement. Anti-ribosomal P antibodies are more associated with neuropsychiatric lupus.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to consider the association between anti-C1q antibodies and specific manifestations of systemic lupus erythematosus (SLE).\n\nAnti-C1q antibodies are autoantibodies directed against the C1q component of the complement system. These antibodies have been studied extensively in SLE and have shown particular clinical significance.\n\nResearch has consistently demonstrated a strong association between anti-C1q antibodies and renal involvement in SLE, specifically:\n\n- Anti-C1q antibodies have high sensitivity and specificity for lupus nephritis\n- They correlate with active renal disease in lupus patients\n- Their titers often rise before clinical flares of nephritis\n- They are particularly associated with proliferative forms of lupus nephritis (Class III and IV)\n\nWhile anti-C1q antibodies may be present in patients with other manifestations of lupus, the strongest and most specific association is with proliferative lupus nephritis.\n\nThe patient's urinalysis showing proteinuria and hematuria is consistent with renal involvement, supporting this association.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-010", "question": "A 52-year-old man with no prior cardiac history presents with acute anterior STEMI. Primary PCI reveals 100% occlusion of the proximal LAD with TIMI 0 flow. After successful stenting with TIMI 3 flow restoration, he develops cardiogenic shock with blood pressure 78/52 mmHg, heart rate 112 bpm, and cardiac index 1.6 L/min/m². Echocardiography shows akinesis of the anterior wall, apex, and septum with EF 20%. He is started on norepinephrine and dobutamine. Despite escalating support, he remains in refractory shock. Which mechanical circulatory support device provides the greatest degree of left ventricular unloading?", "options": ["Intra-aortic balloon pump", "Impella CP", "TandemHeart", "Veno-arterial ECMO", "Impella 5.5"], "answer": "E", "answer_index": 4, "explanation": "Impella 5.5 provides up to 5.5 L/min of forward flow and the greatest degree of LV unloading among the options by actively aspirating blood from the LV and ejecting it into the ascending aorta. This reduces LV end-diastolic pressure, wall stress, and myocardial oxygen demand while maintaining systemic perfusion. VA-ECMO provides excellent systemic support but increases LV afterload and may worsen pulmonary edema without LV venting. TandemHeart provides good support but requires transseptal puncture. Impella CP provides only 3-4 L/min. IABP provides modest afterload reduction with minimal flow augmentation (0.5 L/min).", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "To answer this question, I need to compare the different mechanical circulatory support devices in terms of their ability to unload the left ventricle.\n\nIntra-aortic balloon pump (IABP) provides modest LV unloading by reducing afterload and improving coronary perfusion, but its flow support is limited (0.5-1 L/min).\n\nImpella CP is a catheter-based microaxial flow pump that directly unloads the LV by pulling blood from the LV and ejecting it into the ascending aorta. It provides moderate unloading with flow rates up to 3.5-4.0 L/min.\n\nTandemHeart is a percutaneous ventricular assist device that diverts blood from the left atrium to the femoral artery, providing good LV unloading with flow rates up to 5 L/min.\n\nVA-ECMO provides excellent systemic perfusion (up to 7 L/min) but actually increases LV afterload and can worsen LV distension without additional venting.\n\nImpella 5.5 is a microaxial flow pump that provides the highest degree of LV unloading among these options, with flow rates up to 5.5 L/min. It is surgically implanted and directly unloads the LV by pumping blood from the LV to the ascending aorta.\n\nThe answer is (E)"}]